Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Transl Med. 2020 Oct 20;18(1):400. doi: 10.1186/s12967-020-02574-8.
Contrast-induced nephropathy (CIN) or contrast-induced acute kidney injury (CI-AKI) is an iatrogenic acute kidney injury observed after intravascular administration of contrast media for intravascular diagnostic procedures or therapeutic angiographic intervention. High risk patients including those with chronic kidney disease (CKD), diabetes mellitus with impaired renal function, congestive heart failure, intraarterial intervention, higher volume of contrast, volume depletion, old age, multiple myeloma, hypertension, and hyperuricemia had increased prevalence of CIN. Although CIN is reversible by itself, some patients suffer this condition without renal recovery leading to CKD or even end-stage renal disease which required long term renal replacement therapy. In addition, both CIN and CKD have been associated with increasing of mortality. Three pathophysiological mechanisms have been proposed including direct tubular toxicity, intrarenal vasoconstriction, and excessive production of reactive oxygen species (ROS), all of which lead to impaired renal function. Reports from basic and clinical studies showing potential preventive strategies for CIN pathophysiology including low- or iso-osmolar contrast media are summarized and discussed. In addition, reports on pharmacological interventions to reduce ROS and attenuate CIN are summarized, highlighting potential for use in clinical practice. Understanding this contributory mechanism could pave ways to improve therapeutic strategies in combating CIN.
对比剂肾病(CIN)或对比剂急性肾损伤(CI-AKI)是在血管内诊断程序或治疗性血管造影介入中血管内给予对比剂后观察到的医源性急性肾损伤。高风险患者包括慢性肾脏病(CKD)、伴有肾功能损害的糖尿病、充血性心力衰竭、动脉内介入、更高剂量的对比剂、血容量减少、高龄、多发性骨髓瘤、高血压和高尿酸血症,这些患者 CIN 的患病率增加。虽然 CIN 本身是可逆的,但有些患者会出现这种情况,导致 CKD 甚至终末期肾病,需要长期肾脏替代治疗。此外,CIN 和 CKD 都与死亡率的增加有关。已经提出了三种病理生理机制,包括直接肾小管毒性、肾内血管收缩和活性氧(ROS)的过度产生,所有这些都会导致肾功能受损。本文总结并讨论了基础和临床研究报告中针对 CIN 病理生理学的潜在预防策略,包括低渗或等渗对比剂。此外,还总结了减少 ROS 和减轻 CIN 的药物干预报告,突出了其在临床实践中的应用潜力。了解这种致病机制可能为改善对抗 CIN 的治疗策略铺平道路。